Study of Neratinib for Patients with HER2-Positive Breast Cancer with Brain Metastases

Selecting and Sequencing of HER2-Targeting Therapies in HER2-Positive Metastatic Breast CancerПодробнее

SABCS22: Rachel Freedman, MD, MPH | Dana-Farber Cancer InstituteПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

Capecitabine Plus Either Neratinib or Lapatinib for Patients With HER2 Breast CancerПодробнее

ELEANOR: real-world use of neratinib in HER2+, early breast cancerПодробнее

ELEANOR interim analysis: real-world study of adjuvant neratinib in HER2+/HR+ early breast cancerПодробнее

ELEANOR: observing real-life extended adjuvant therapy with neratinib and concurrent use of CONKADOПодробнее

ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее

Metastatic Breast Cancer: Leveraging Clinical Pathways to Navigate a Complex Treatment Landscape:Подробнее

HER2 In Breast Cancer: Testing Guidelines and New Treatment ApproachesПодробнее

Can we prevent brain metastases in breast cancer?Подробнее

Treating HER2+ breast cancer with brain metastasesПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Traina & Dr. CareyПодробнее

Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast CancerПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

2021 West Oncology | Breast Cancer | Update on Brain MetastasesПодробнее

Brain metastases in HER2+ breast cancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. SolimanПодробнее